Biotechnology

Rigel Pharmaceuticals

$3.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.27%) Today
+$0.02 (+0.53%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RIGL and other stocks, options, and ETFs commission-free!

About RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. The listed name for RIGL is Rigel Pharmaceuticals, Inc. Common Stock.

CEO
Raul R. Rodriguez
Employees
163
Headquarters
South San Francisco, California
Founded
1996
Market Cap
638.75M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.80M
High Today
$3.83
Low Today
$3.71
Open Price
$3.82
Volume
1.88M
52 Week High
$5.24
52 Week Low
$1.23

Collections

RIGL Earnings

-$0.14
-$0.05
$0.04
$0.13
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 2, After Hours

You May Also Like

FITBO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure